Limited influences of chemotherapy on healthy and metastatic liver parenchyma

Table 1 Colorectal cancer patients’ characteristics

	Number
Sex (M/F)	27/12
Location
Sigmoid	12
Rectum	6
Rectosigmoid	4
Cecum	4
Colon ascendens	3
Colon descendens	1
Splenic feature	2
Bauhin’s valve	1
Not specified	6

Table 2 Twenty-three patients received chemotherapy before the liver resection

Type of chemotherapy	Number
5-FU, LV, oxaliplatin	7
5-FU, LV, CPT-11	2
5-FU, LV	5
Cetuximab, FOLFIRI	1
Cetuximab, CPT-11	1
CPT-11	1
Oxaliplatin, capecitabine, CPT-11	1
Others	5

5-FU: 5-fluorouracil, LV: leucovorin

Table 3 Positive staining of the adhesion molecules in normal and metastatic liver parenchyma

	Normal (%)	Metastatic (%)
E-cadherin	39/39 (100)	37/38 (97.37)
β-catenin	35/39 (89.74)	36/38 (94.74)
γ-catenin	18/39 (46.15)	25/38 (65.79)
VEGF	39/39 (100)	32/38 (84.21)
p53	0/39 (0)	25/38 (65.79)

Table 4 Expression of the adhesion molecules in normal and metastatic liver parenchyma (median and range)

	Normal		Metastatic
	Chemotherapy (n = 23)	No chemotherapy (n = 16)	Chemotherapy (n = 23)	No chemotherapy (n = 16)
E-cadherin	3 (2-4)	3 (2-6)	3 (0-6)	4 (2-6)
β-catenin	3 (0-5)	3 (0-5)	6 (0-6)	5 (0-6)
γ-catenin	0 (0-3)	1 (0-2)	2 (0-4)	2 (0-4)
VEGF	5 (3-5)	5 (3-5)	4 (0-5)	3 (0-4)
p53	0 (0-0)	0 (0-0)	3 (0-6)	2.5 (0-6)

Table 5 Percentage of macro- and microvesicular steatosis (median and range)

	Chemotherapy (n = 23, %)	No chemotherapy (n = 16, %)
Macrovesicular	10 (0-40)	10 (0-30)
Microvesicular	0 (0-10)	0 (0-10)